PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item 5.02. Departure of Certain Officers or Directors; Election
of Directors; Appointment of Certain Officers; Compensation
Arrangements of Certain Officers

On Feb 3, 2017, the Board of Directors of Petlife
Pharmaceuticals, Inc. (the Company) appointed Geoffrey Broderick
as the President of Company.

Mr. Broderick, with over 25 years of business experience and
multiple degrees, is a Product Development expert, a Business
Consultant, and a Legal Advisor. Having augmented his
professional expertise on state, national, and international
levels, Broderick has also had a substantive career well beyond
his professions. Becoming a commissioned officer in the Army
National Guard and graduating from Officer Candidate School with
honors, Mr. Broderick has valuable leadership skills, which will
very much be an asset to Company. Company expects to quickly
capitalize on Geoffreys experience, talents, connections, and
family history.

Geoffreys family started the entire Natural Pet Food category
back in the 70s, so his Product-Dev career got an early start
with him developing the very first Antioxidant Supplement for
pets, and eventually he formulated, designed, and created the
very first super-premium wild bird food, which ended up becoming
the official bird food of the National Wildlife Federation, the
largest wildlife organization on the planet. Over the years, he
has used his talents, education, and experience to successfully
lead several other companies, organizations, and firms through
all stages of their transitional development. I specifically
chose him to do the same for Company.

As a pioneer in the Pet, Veterinary, Wild Bird, Consumer Product,
and Nutritional categories, Mr. Broderick has had extensive
employment and entrepreneurial experience surrounding the
development, legal, and compliance aspects of many industries,
including natural foods, cosmetics, pharmaceuticals,
nutraceuticals, consumer products, consumer healthcare, consumer
(and pet) manufacturing, and the global pet food industry (as a
whole). Intertwined with his Product-Dev and Business-Dev skills,
he has extensive experience with the legal/compliance
requirements of all levels of marketing from manufacturing,
warehousing, and distribution, to retail.

With his dad being a famous veterinarian, pets have always been a
big part of Geoffreys life. His interest in PetLife stems from
his love for animals. My dad has spent the last 50 years
developing the products to help prevent cancer and significantly
prolong the lives of pets all around the world, so, when I heard
about PetLife, how could I not get involved?

Geoffrey alongside his business expertise and professional
proficiencies, is also academically well-accomplished, and (with
several degrees, including an MBA and Doctorate) he feels he can
bring his corporate experience and Product Development skills to
the core of PetLife. He stated, I dont believe Ive ever seen a
company with such potential, while at the same time being such a
perfect fit for everything I can bring to the table. He adds, Im
ready to make a difference!

About PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF)

PetLife Pharmaceuticals, Inc., formerly Clear TV Ventures, Inc., is engaged in the development and launching of a high potency (HP) veterinary cancer medications and nutraceuticals, based on the formula Escozine. The Company’s formula, Escozine (for humans) is sold as either a nutraceutical or prescription drug in approximately 40 countries, including the United States. It has rights to formulate, package and market a product line, Escozine for Pets, for livestock suffering from cancer. Escozine for Pets is a natural product containing serum derived from the Caribbean Blue Scorpion and polarized using the Company’s polarization technology. It intends to target various veterinary cancers, including Lymphoma, Osteosarcoma, Mast Cell Tumor, Melanoma, Squamous Cell Carcinoma, Mammary Carcinoma, Transitional Cell Carcinoma and Soft Tissue Sarcoma. It has designed three products for differentiated intake protocols for home and veterinary usage: Oral/Rectal, Patch and Injectable.

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) Recent Trading Information

PetLife Pharmaceuticals, Inc. (OTCMKTS:PTLF) closed its last trading session up +0.098 at 0.178 with 5,003 shares trading hands.

An ad to help with our costs